Only one other ITSN2 (exon 29)-ALK (exon 18) fusion has been reported so far, specifically in a patient with thyroid cancer.33 In that case, RNA-Seq showed overexpression of ALK exons 18-29 downstream of the fusion point; however, neither IHC results nor the therapeutic effects of ALK-TKIs were reported. The gene discussed is ALK; the disease is thyroid cancer.